Nasal Care Articles & Analysis
2 news found
XF-73 Nasal targeting peak sales potential of $1 billion in its major target markets Phase 3 patient recruitment could start in 2024 subject to completing an XF-73 Nasal partnering deal in 2023 XF-73 Nasal is the lead drug candidate developed from Destiny Pharma’s XF platform and it is initially being developed for the prevention of ...
We are hopeful that this collaboration will bring new opportunities for healthcare professionals to provide their patients with the highest level of care.” Commenting on the new arrangement, Dorian Drake’s President, Ed Dorian Jr. said, “Bionix stands apart from many of its competitors in product quality, design and innovation in the areas of ear ...